| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM199808273390903 |
| P698 | PubMed publication ID | 9718377 |
| P2093 | author name string | Bolton WK | |
| Nissenson AR | |||
| Schwab SJ | |||
| Goodkin DA | |||
| Egrie JC | |||
| Besarab A | |||
| Browne JK | |||
| Okamoto DM | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart disease | Q190805 |
| hemodialysis patient | Q126109077 | ||
| P304 | page(s) | 584-590 | |
| P577 | publication date | 1998-08-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin | |
| P478 | volume | 339 |
| Q37390006 | A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy |
| Q39287129 | A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada |
| Q35633171 | A dosing algorithm for erythropoietin alpha in older adults with heart failure and a preserved ejection fraction |
| Q37000231 | A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. |
| Q50512562 | A model of erythropoiesis in adults with sufficient iron availability. |
| Q36001255 | A novel protective effect of erythropoietin in the infarcted heart |
| Q48422677 | A physician's perseverance uncovers problems in a key nephrology study |
| Q43606194 | A pilot study of darbepoetin alfa for prophylactic neuroprotection in aortic surgery |
| Q48737545 | A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). |
| Q37626692 | A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). |
| Q33985849 | A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment |
| Q51023440 | A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta. |
| Q54961659 | A threshold trajectory was revealed by isolating the effects of hemoglobin rate of rise in anemia of chronic kidney disease. |
| Q22306349 | ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...] |
| Q60918869 | Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis |
| Q48338769 | Administration of IL-1ra improves adiponectin levels in chronic hemodialysis patients |
| Q34555348 | Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients |
| Q28083408 | Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS |
| Q38109321 | Alternatives to blood transfusion |
| Q35682147 | American Society of Nephrology Quiz and Questionnaire 2014: RRT. |
| Q35876060 | An integrated approach to prognosis using protein microarrays and nonparametric methods |
| Q34398392 | An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients. |
| Q34896347 | An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost |
| Q43013351 | Anaemia and heart failure |
| Q47325190 | Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). |
| Q38059457 | Anaemia in inflammatory rheumatic diseases |
| Q35836904 | Anaemia in kidney disease: harnessing hypoxia responses for therapy |
| Q73905508 | Anaemia is an independent predictor of poor outcome in patients with chronic heart failure |
| Q38084470 | Anaemia management and mortality risk in chronic kidney disease |
| Q33412594 | Anaemia management with subcutaneous epoetin delta in patients with chronic kidney disease (predialysis, haemodialysis, peritoneal dialysis): results of an open-label, 1-year study |
| Q51318153 | Anaemia: Does the KDIGO guideline move the needle in CKD anaemia? |
| Q44067854 | Anaemia: The safety and efficacy of peginesatide in patients with CKD. |
| Q37187390 | Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease? |
| Q36560971 | Anemia and cardiovascular disease in diabetic nephropathy |
| Q36659505 | Anemia and diabetic nephropathy |
| Q36203102 | Anemia and heart failure |
| Q35252704 | Anemia and heart failure: a cause of progression or only a consequence? |
| Q35553278 | Anemia as a risk factor for cardiovascular disease |
| Q79635047 | Anemia in children with chronic kidney disease |
| Q36689806 | Anemia in diabetes: marker or mediator of microvascular disease? |
| Q80093106 | Anemia in patients with chronic kidney disease: defining the optimal hemoglobin target |
| Q44011684 | Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure |
| Q39822858 | Anemia management in chronic kidney disease |
| Q35553274 | Anemia of chronic disease: Past, present, and future |
| Q24651385 | Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? |
| Q80532457 | Anemia of chronic kidney disease: CHOIR and the FDA |
| Q82522796 | Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure |
| Q37134171 | Anemia treatment in chronic kidney disease: shifting uncertainty |
| Q83042225 | Anemia trials: lessons for clinicians, politicians, and third-party payers |
| Q36547312 | Anemia, chronic renal disease and congestive heart failure--the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists |
| Q84120977 | Anemia: To TREAT or not to TREAT--that is the question |
| Q84120974 | Anemia: What can we learn from a secondary analysis of CHOIR? |
| Q36765940 | Angina pectoris and intensive intravenous iron treatment in hemodialysis patients. |
| Q42379422 | Antihypertensive Medication in Patients Pre- and Postdialysis: Still Hazy After All These Years. |
| Q37792718 | Antiviral therapy in HCV-infected decompensated cirrhotics |
| Q37674518 | Arteriovenous Access Failure, Stenosis, and Thrombosis. |
| Q33757650 | Assessing the quality of prescribing and monitoring erythropoiesis-stimulating agents in the nursing home setting. |
| Q35858118 | Association Between Vascular Access Dysfunction and Subsequent Major Adverse Cardiovascular Events in Patients on Hemodialysis: A Population-Based Nested Case-Control Study |
| Q42218133 | Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients |
| Q34094710 | Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors |
| Q84043487 | Association between repeat hospitalization and early intervention in dialysis patients following hospital discharge |
| Q35587399 | Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease |
| Q58130103 | Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM - HD Study |
| Q35987846 | Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients |
| Q36423854 | Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition Study |
| Q37336993 | Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease |
| Q33906186 | Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis |
| Q37097855 | Association of hemoglobin with ankle-brachial index in general population |
| Q35664160 | Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis |
| Q37213727 | Associations of anemia persistency with medical expenditures in Medicare ESRD patients on dialysis |
| Q38415942 | Autologous blood transfusion for hemodialysis patients: A case report and review of clinical reports and therapeutic features |
| Q36679566 | Autologous peripheral blood-derived mononuclear cells induced by erythropoietin improve critical ischemic limbs |
| Q41036235 | Balancing the Evidence: How to Reconcile the Results of Observational Studies vs. Randomized Clinical Trials in Dialysis |
| Q37781412 | Bench to bedside: A role for erythropoietin in sepsis. |
| Q36552129 | Biomarkers and surrogate endpoints in clinical trials |
| Q33411363 | Blood disorders after kidney transplantation |
| Q37476741 | Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study |
| Q24187385 | Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients |
| Q24244091 | Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients |
| Q37182739 | Calcimimetics in chronic kidney disease: evidence, opportunities and challenges |
| Q36415312 | Cancer-related anemia and recombinant human erythropoietin--an updated overview |
| Q54282807 | Candidate biomarkers for erythropoietin response in end-stage renal disease. |
| Q41398632 | Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat. |
| Q42434368 | Cardio-renal anemia syndrome. |
| Q38068097 | Cardiorenal syndrome: pathophysiology and potential targets for clinical management |
| Q34453236 | Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs |
| Q84563746 | Cardiovascular disease in patients with chronic kidney disease |
| Q30435143 | Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction |
| Q37454373 | Cardiovascular risk and management in chronic kidney disease |
| Q37557361 | Cardiovascular risk factors in patients with chronic kidney disease |
| Q36306246 | Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors |
| Q79868587 | Challenging the boundaries of anemia management: a balanced approach to i.v. iron and EPO therapy |
| Q47807405 | Change in quality of life and one-year mortality risk in maintenance dialysis patients |
| Q47307196 | Changes in Excess Mortality from End Stage Renal Disease in the United States from 1995 to 2013. |
| Q43591504 | Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. |
| Q44070472 | Changes in dialysis treatment modalities during institution of flat rate reimbursement and quality assurance programs |
| Q38433010 | Changes to the end-stage renal disease quality incentive program |
| Q87393433 | Chapter 3: Use of ESAs and other agents to treat anemia in CKD |
| Q33767504 | Characteristics and outcomes among heart failure patients with anemia and renal insufficiency with and without blood transfusions (public discharge data from California 2000-2006) |
| Q33624998 | Characteristics and performance of minority-serving dialysis facilities |
| Q46206517 | Choice of dialysis modality |
| Q37695746 | Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question |
| Q34631631 | Chronic kidney disease |
| Q36776175 | Chronic kidney disease and its complications |
| Q37332267 | Chronic kidney disease mineral bone disorder and health-related quality of life among incident end-stage renal-disease patients |
| Q37217352 | Chronic kidney disease, heart failure and anemia |
| Q44038686 | Chronic kidney disease: Are elevated doses of ESAs associated with adverse outcomes? |
| Q84190747 | Chronic kidney disease: Association between ESA use and stroke in patients with CKD |
| Q37784542 | Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease |
| Q35129832 | Chronic renal insufficiency and renoprotective strategies |
| Q63681898 | Clinical Practice Guidelines for evidence-based use of erythropoietic-stimulating agents |
| Q63681899 | Clinical Practice Guidelines for supplemental therapies and issues |
| Q42042945 | Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease |
| Q35938500 | Clinical and economic impact of epoetins in cancer care |
| Q37280782 | Clinical factors and the decision to transfuse chronic dialysis patients |
| Q36616210 | Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device |
| Q40074935 | Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). |
| Q37641052 | Clinical relevance of FGF-23 in chronic kidney disease |
| Q35530060 | Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects. |
| Q37601476 | Comparative effectiveness of two anemia management strategies for complex elderly dialysis patients |
| Q64912317 | Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients. |
| Q38754842 | Comparing the Effectiveness of Dynamic Treatment Strategies Using Electronic Health Records: An Application of the Parametric g-Formula to Anemia Management Strategies |
| Q61806038 | Comparison of Clopidogrel and Ticlopidine/ in Patients With Clopidogrel Resistance and Carotid Stenting |
| Q41261548 | Comparison of Hemoglobin Levels Before and After Hemodialysis and Their Effects on Erythropoietin Dosing and Cost. |
| Q36314982 | Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy |
| Q82455364 | Complete correction of anemia by erythropoiesis-stimulating agents is associated with insulin resistance in hemodialysis patients |
| Q90311779 | Compliance With Biochemical Objectives in Patients on Renal Replacement Therapy Before Kidney Transplantation in Mexico |
| Q37808688 | Confusion about the Appropriate Use of Erythropoiesis-Stimulating Agents in Patients Undergoing Maintenance Dialysis |
| Q35107199 | Congestive Heart Failure in Patients with Chronic Kidney Disease and on Dialysis |
| Q28088564 | Considerations and challenges in defining optimal iron utilization in hemodialysis |
| Q39331265 | Considerations and controversies in managing chronic kidney disease: An update |
| Q24202919 | Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease |
| Q38637669 | Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. |
| Q33638138 | Continuous quality improvement in daily clinical practice: a proof of concept study |
| Q36165015 | Correlation between CRP and early failure of arteriovenous fistula (AVF). |
| Q43778426 | Correlation between carotid intima-media thickness and hematocrit and hemoglobin values in renal transplant recipients. |
| Q88495704 | Cost-Utility Analysis of Erythropoietin for Anemia Treatment in Thai End-Stage Renal Disease Patients with Hemodialysis |
| Q33874659 | Cost-effectiveness of continuous erythropoietin receptor activator in anemia |
| Q34596211 | Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. |
| Q87203898 | Darbepoetin alfa once every 2 weeks effectively maintained hemoglobin in dialysis patients in an observational study: Austrian cohort of ALTERNATE |
| Q24197780 | Darbepoetin for the anaemia of chronic kidney disease |
| Q45065477 | De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease |
| Q50067304 | Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. |
| Q36825061 | Design of the Blood Pressure Goals in Dialysis pilot study |
| Q34399172 | Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. |
| Q33645279 | Determining Optimum Hemoglobin Sampling for Anemia Management from Every-Treatment Data |
| Q37764741 | Diabetes, anemia and CKD: Why TREAT? |
| Q35107214 | Diagnosis and Therapy of Coronary Artery Disease in Renal Failure, End-Stage Renal Disease, and Renal Transplant Populations |
| Q84130173 | Dialysis: Phosphorus binders and survival: need for randomized trials |
| Q85237852 | Difference between true functional haemoglobin and pre-dialysis haemoglobin is associated with plasma volume variation: a multicentre study |
| Q37019516 | Different analyses estimate different parameters of the effect of erythropoietin stimulating agents on survival in end stage renal disease: a comparison of payment policy analysis, instrumental variables, and multiple imputation of potential outcome |
| Q36973268 | Does correction of anemia slow the progression of chronic kidney disease? |
| Q80166596 | Does full versus partial correction of anemia have additional cardiac benefit in incident hemodialysis patients? |
| Q36476556 | Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis |
| Q87502344 | Drug development: how academia, industry and authorities interact |
| Q36920662 | Drug-induced cardiovascular disorders |
| Q42389549 | ESRD Payment Reform: First Do No Harm |
| Q51161181 | Early mortality in patients starting dialysis appears to go unregistered. |
| Q35985870 | Early outcomes among those initiating chronic dialysis in the United States |
| Q24187089 | Early versus delayed erythropoietin for the anaemia of end-stage kidney disease |
| Q37123128 | Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL |
| Q35670734 | Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents |
| Q57171158 | Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis |
| Q35083047 | Effect of erythropoiesis-stimulating agents on blood pressure in pre-dialysis patients |
| Q34700889 | Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients |
| Q36115205 | Effect of processing and storage on red blood cell function in vivo |
| Q90594296 | Effects of Molidustat in the Treatment of Anemia in CKD |
| Q74291235 | Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure |
| Q36824720 | Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease |
| Q33992079 | Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol |
| Q88408932 | Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents |
| Q42803012 | Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study |
| Q28547636 | Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis |
| Q92218228 | Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial |
| Q33446829 | End stage renal disease. |
| Q33850437 | End-stage renal disease |
| Q34677226 | Endocrine abnormalities in chronic renal failure |
| Q37237936 | Endothelial Progenitor Cell Levels Predict Future Physical Function: An Exploratory Analysis From the VA Enhanced Fitness Study |
| Q34328779 | Endotoxaemia in haemodialysis: a novel factor in erythropoetin resistance? |
| Q38214140 | Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure |
| Q40886101 | Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform |
| Q46134791 | Epoetin Alfa: A Cause of Coronary Artery Thrombosis |
| Q37481924 | Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events |
| Q90250420 | Erythropoiesis-Stimulating Agents and Mortality |
| Q61449909 | Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective |
| Q33620577 | Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13. |
| Q34997753 | Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients |
| Q37279813 | Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective |
| Q33890476 | Erythropoiesis-stimulating agent use after changes in medicare reimbursement policies |
| Q35642998 | Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes |
| Q24187413 | Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis |
| Q24241045 | Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients |
| Q33630871 | Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes |
| Q37098040 | Erythropoietic agents and the elderly |
| Q37437142 | Erythropoietic stress and anemia in diabetes mellitus |
| Q86260187 | Erythropoietin |
| Q34336393 | Erythropoietin Combined with Liposomal Amphotericin B Improves Outcome during Disseminated Aspergillosis in Mice |
| Q36958826 | Erythropoietin Dose and Mortality in Hemodialysis Patients: Marginal Structural Model to Examine Causality |
| Q77823368 | Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA end-stage renal disease core indicators project |
| Q35909929 | Erythropoietin in brain development and beyond |
| Q36142638 | Erythropoietin mimics ischemic preconditioning |
| Q34164787 | Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma! |
| Q24240202 | Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data |
| Q39732359 | Erythropoietin suppresses epithelial to mesenchymal transition and intercepts Smad signal transduction through a MEK-dependent mechanism in pig kidney (LLC-PK1) cell lines |
| Q47873221 | Erythropoietin therapy after out-of-hospital cardiac arrest: A systematic review and meta-analysis. |
| Q37152506 | Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis |
| Q37152501 | Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial |
| Q36516298 | Erythropoietin update 2011 |
| Q33881779 | Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis |
| Q33655326 | Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness |
| Q37952603 | Erythropoietin: a future therapy for failing hearts? |
| Q37072568 | Erythropoietin: physiology and molecular mechanisms |
| Q37123117 | Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States |
| Q42574455 | Estimating cerebral blood volume with expanded vascular space occupancy slice coverage |
| Q58616748 | Evaluating the Evidence behind Policy Mandates in US Dialysis Care |
| Q64074855 | Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing |
| Q27023274 | Evidence for the prevention and treatment of stroke in dialysis patients |
| Q37340239 | Evidence-based cardiology in hemodialysis patients |
| Q42619825 | Exploring the Relationships between Hemoglobin, the Endothelium and Vascular Health in Patients with Chronic Kidney Disease |
| Q33854988 | Extended dosing of darbepoetin alfa in peritoneal dialysis patients |
| Q51793085 | Extraordinary popular delusions and the madness of crowds: puncturing the epoetin bubble--lessons for the future |
| Q34041146 | FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia |
| Q36104846 | Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. |
| Q36677375 | Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin |
| Q35985743 | Flow-mediated vasodilation in end-stage renal disease |
| Q36746039 | Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia |
| Q24194545 | Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients |
| Q42419216 | From Phosphaturia to Cardiovascular Protection: Is Fibroblast Growth Factor-23 the Heart of the Matter? |
| Q39977624 | Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients |
| Q36736661 | Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients |
| Q33926530 | HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism |
| Q24244250 | Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease |
| Q24250243 | Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease |
| Q93161548 | Haemoglobin concentration and survival of haemodialysis patients before and after experiencing cardiovascular disease: a cohort study from Japanese dialysis outcomes and practice pattern study (J-DOPPS) |
| Q79451156 | Haemoglobin concentrations in chronic kidney disease |
| Q59167772 | Haemoglobin targets: we were wrong, time to move on |
| Q37042056 | Health-related quality of life and hemoglobin levels in chronic kidney disease patients |
| Q26824149 | Heart failure in patients with chronic kidney disease: a systematic integrative review |
| Q41185791 | Heart failure: chapter 3. Underlying pathology in heart failure 'Failure of the circulation versus failure of the heart' |
| Q37801709 | Hemodialysis Vascular Access Training and Practices Are Key to Improved Access Outcomes |
| Q37926899 | Hemodialysis in children with end-stage renal disease |
| Q37477281 | Hemodialysis vascular access monitoring: current concepts |
| Q40665725 | Hemoglobin Concentration and Risk of Incident Stroke in Community-Living Adults |
| Q91708883 | Hemoglobin and erythrocyte count are independently and positively associated with arterial stiffness in a community-based study |
| Q43976222 | Hemoglobin and hematocrit at the end of hemodialysis: a better way to adjust erythropoietin dose? |
| Q46099868 | Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease |
| Q44506485 | Hemoglobin level and risk of hospitalization and mortality in children on peritoneal dialysis |
| Q36666967 | Hemoglobin level variability: associations with mortality |
| Q53139367 | Hemoglobin target in chronic kidney disease: a pediatric perspective. |
| Q36947393 | Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy |
| Q27023213 | Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis |
| Q59796108 | Hemoglobin targets for the anemia in patients with dialysis-dependent chronic kidney disease: a meta-analysis of randomized, controlled trials |
| Q34455408 | Hemoglobin variability does not predict mortality in European hemodialysis patients |
| Q36475617 | Hemoglobin variability with epoetin beta and continuous erythropoietin receptor activator in patients on peritoneal dialysis. |
| Q35094773 | Hemorheology and microvascular disorders |
| Q91850857 | High Cardiovascular Risk Profile in Young Patients on the Kidney Transplant Waiting List |
| Q36290116 | High Dose ESAs Are Associated with High iPTH Levels in Hemodialysis Patients with End-Stage Kidney Disease: A Retrospective Analysis |
| Q36799806 | High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes |
| Q92320125 | High sensitivity Troponin-I levels in asymptomatic hemodialysis patients |
| Q24200387 | High-flux versus low-flux membranes for end-stage kidney disease |
| Q38763700 | History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology |
| Q36662013 | History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients |
| Q44266370 | Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study |
| Q48140646 | Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease. |
| Q34695324 | IL-1β receptor antagonist reduces inflammation in hemodialysis patients |
| Q73566942 | IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000 |
| Q28548561 | Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease |
| Q36209104 | Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR |
| Q57189952 | Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives |
| Q35791745 | Implications of a reduction in the hemoglobin target in erythropoiesis-stimulating agent-treated hemodialysis patients |
| Q37553103 | Improving outcomes for ESRD patients: shifting the quality paradigm |
| Q37401806 | In Vitro Evaluation of the Link Between Cell Activation State and Its Rheological Impact on the Microscale Flow of Neutrophil Suspensions |
| Q79653175 | Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer |
| Q44431120 | Increased blood viscosity is associated with reduced renal function and elevated urinary albumin excretion in essential hypertensives without chronic kidney disease |
| Q46104690 | Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin |
| Q95595689 | Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience |
| Q40329273 | Individualizing anaemia therapy |
| Q98178903 | Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS) |
| Q36765955 | Inflammation and anaemia as predictors of cardiovascular mortality in hemodialysis patients |
| Q34604651 | Influence of progressive renal dysfunction in chronic heart failure |
| Q34911240 | Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series |
| Q47434892 | Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients. |
| Q37052058 | International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study. |
| Q33371531 | Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia |
| Q24273399 | Interpreting Results of Clinical Trials: A Conceptual Framework |
| Q35810739 | Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. |
| Q24200248 | Interventions for erythropoietin-resistant anaemia in dialysis patients |
| Q84611960 | Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients |
| Q42154280 | Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model |
| Q36364317 | Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial |
| Q40548437 | Intravenous iron administration strategies and anemia management in hemodialysis patients |
| Q36669039 | Introduction: improving outcomes in chronic kidney disease. |
| Q89636084 | Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment |
| Q37117678 | Iron and anemia in human biology: a review of mechanisms |
| Q28388335 | Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases |
| Q38040656 | Iron deficiency anemia in heart failure |
| Q46532958 | Iron deficiency in non-dialysis chronic kidney disease |
| Q35022235 | Iron dosing in kidney disease: inconsistency of evidence and clinical practice |
| Q43083175 | Iron in heart failure: friend or foe? |
| Q37262853 | Iron indices and survival in maintenance hemodialysis patients with and without polycystic kidney disease |
| Q35857178 | Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. |
| Q33958582 | Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease patients independent of erythropoiesis-stimulating agent use: a retrospective cohort study |
| Q34333986 | Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects |
| Q37801274 | Iron supplementation to treat anemia in patients with chronic kidney disease |
| Q36745326 | Iron treatment and the TREAT trial |
| Q43236775 | Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD. |
| Q84859522 | Is there a deleterious effect of erythropoietin in end-stage renal disease? |
| Q37415688 | Key comorbid conditions that are predictive of survival among hemodialysis patients |
| Q39977619 | Key insights into present and future treatments of anaemia in CKD patients |
| Q35573726 | Left ventricular dysfunction in the haemodialysis population. |
| Q37477724 | Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. |
| Q79267929 | Left ventricular hypertrophy: a surrogate end point or correlate of cardiovascular events in kidney disease? |
| Q55266280 | Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia. |
| Q58561315 | Lipid management in patients with chronic kidney disease |
| Q35073857 | Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib |
| Q99710988 | Low rather than high mean corpuscular volume is associated with mortality in Japanese patients under hemodialysis |
| Q36294113 | Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial. |
| Q35868691 | Low-Dose Treatment with Erythropoiesis-Stimulating Agents and Cardiovascular Geometry in Chronic Kidney Disease: Is Darbepoetin-α More Effective than Expected? |
| Q33898717 | Macrocytosis may be associated with mortality in chronic hemodialysis patients: a prospective study |
| Q82729789 | Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study |
| Q35735258 | Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status |
| Q36719231 | Management of anemia in children receiving chronic peritoneal dialysis |
| Q38134288 | Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease |
| Q38121827 | Management of neurogenic orthostatic hypotension in patients with autonomic failure |
| Q80863092 | Managing anemia in dialysis patients: hemoglobin cycling and overshoot |
| Q33797640 | Managing anemia in patients with chronic heart failure: what do we know? |
| Q36443751 | Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials |
| Q37157237 | Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide |
| Q55379461 | Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease. |
| Q33600121 | Mechanism of erythropoietin-induced hypertension |
| Q37038424 | Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure |
| Q27693202 | Mechanisms of anemia in CKD. |
| Q36600985 | Mechanisms of disease: erythropoietin--an old hormone with a new mission? |
| Q37082467 | Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy |
| Q50119222 | Medical safety in the care of the person with end-stage kidney disease |
| Q37154109 | Medicare's payment strategy for end-stage renal disease now embraces bundled payment and pay-for-performance to cut costs |
| Q36265484 | Medication adherence in randomized controlled trials evaluating cardiovascular or mortality outcomes in dialysis patients: A systematic review |
| Q84122396 | Mitigating the cardiovascular risk of anemia in patients with type 2 diabetes and CKD: Does darbepoetin help? The TREAT Trial |
| Q36482963 | Modulation of stroke risk in chronic kidney disease. |
| Q33999246 | Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. |
| Q40245317 | Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis |
| Q34306104 | Mortality in dialysis patients may not be associated with ESA dose: a 2-year prospective observational study |
| Q37397724 | Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study |
| Q34281518 | Nadir hemoglobin levels after discontinuation of epoetin in hemodialysis patients |
| Q34534923 | Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients |
| Q36863406 | Negative trials in nephrology: what can we learn? |
| Q53335433 | Neurocognitive function and quality of life in relation to hematocrit levels in chronic hemodialysis patients. |
| Q38522683 | Nitric oxide in the human respiratory cycle. |
| Q38112049 | Nitric oxide transport in blood: a third gas in the respiratory cycle |
| Q83324452 | Nonhypotensive dose of beta-adrenergic blocker ameliorates capillary deficits in the hearts of rats with moderate renal failure |
| Q37282300 | Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease |
| Q73769750 | Normalization of hematocrit in hemodialysis patients does not affect silent ischemia |
| Q41669033 | Normalizing hematocrit in dialysis patients improves brain function |
| Q33256941 | Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia |
| Q46149455 | Novel techniques and innovation in blood purification: a clinical update from Kidney Disease: Improving Global Outcomes |
| Q55416565 | Obesity may be erythropoietin dose-saving in hemodialysis patients. |
| Q36522468 | Obesity paradox in end-stage kidney disease patients |
| Q30423049 | Observational studies versus randomized controlled trials: avenues to causal inference in nephrology |
| Q46186819 | Olmesartan clinical trial in Okinawan patients under OKIDS (OCTOPUS) study: design and methods |
| Q33392426 | Optimal and continuous anaemia control in a cohort of dialysis patients in Switzerland |
| Q88207162 | Optimal hematocrit based on regional cerebral blood flow in hemodialysis patients with diabetic nephropathy |
| Q47954573 | Optimal hematocrit in an artificial microvascular network |
| Q36061854 | Optimal hemoglobin level for anemia treatment in a cohort of hemodialysis patients |
| Q91815892 | PIVOTAL trial: iron loading improves clinical outcomes |
| Q34085240 | Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury |
| Q33808512 | Parenteral iron use in the management of anemia in end-stage renal disease patients |
| Q37123216 | Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients |
| Q34713632 | Past, present and future of erythropoietin use in the elderly |
| Q33691308 | Patient satisfaction with in-centre haemodialysis care: an international survey |
| Q36733554 | Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa |
| Q35944877 | Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients |
| Q43116165 | Performance variability of seven commonly used self-monitoring of blood glucose systems: clinical considerations for patients and providers |
| Q36860265 | Pharmacist's role in managing anemia in patients with chronic kidney disease: potential clinical and economic benefits |
| Q26829812 | Pharmacologic management of chronic reno-cardiac syndrome |
| Q38704713 | Pharmacological targeting of the HIF hydroxylases--A new field in medicine development |
| Q53383073 | Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. |
| Q97527917 | Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis |
| Q36144411 | Pleiotropic renal actions of erythropoietin |
| Q37530419 | Posttransplant anemia: the role of sirolimus |
| Q77763078 | Potential cost savings of erythropoietin administration in end-stage renal disease |
| Q58696069 | Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis |
| Q47118771 | Predictors of adherence to a new erythropoiesis-stimulating agent inpatient ordering policy: A cross-sectional study. |
| Q37214510 | Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients |
| Q35685985 | Predictors of quality of life of hemodialysis patients in India |
| Q34017119 | Premature cardiovascular disease in chronic renal failure |
| Q34124684 | Preoperative hemoglobin and outcomes in patients with CKD undergoing cardiac surgery |
| Q33871590 | Pretransplantation erythropoiesis-stimulating agent hyporesponsiveness is associated with increased kidney allograft failure and mortality |
| Q50989985 | Pretreatment with erythropoietin attenuates the neurological injury after spinal cord ischemia. |
| Q34770416 | Prevalence of ventricular arrhythmia and its associated factors in nondialyzed chronic kidney disease patients |
| Q44125448 | Prognostic significance of left ventricular hypertrophy observed at dialysis initiation depends on the pre-dialysis use of erythropoiesis-stimulating agents |
| Q89521025 | Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia |
| Q30874431 | Protecting the confidentiality of interim data: addressing current challenges |
| Q35201722 | Protective effect of erythropoietin against myocardial injury in rats with sepsis and its underlying mechanisms |
| Q83575095 | Proteinuria as a surrogate end point--more data are needed |
| Q57282391 | Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data |
| Q34031364 | Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis |
| Q48225857 | Rational Management of Iron-Deficiency Anaemia in Inflammatory Bowel Disease |
| Q33890794 | Real-World Impact of Cardiovascular Disease and Anemia on Quality of Life and Productivity in Patients with Non-Dialysis-Dependent Chronic Kidney Disease |
| Q26849298 | Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease |
| Q37230276 | Recombinant human epoetin beta in the treatment of chemotherapy-related anemia |
| Q36661294 | Recombinant human epoetin beta in the treatment of renal anemia |
| Q44730385 | Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials |
| Q57165825 | Recommendations on RBC Transfusion in General Critically Ill Children Based on Hemoglobin and/or Physiologic Thresholds From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative |
| Q90333662 | Red Blood Cell Dysfunction in Critical Illness |
| Q30275352 | Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia |
| Q27021803 | Red cell physiology and signaling relevant to the critical care setting |
| Q38072533 | Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new. |
| Q37063716 | Regulation of erythropoiesis by hypoxia-inducible factors |
| Q51907157 | Relation between level or change of hemoglobin and generic and disease-specific quality of life measures in hemodialysis. |
| Q28468446 | Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study |
| Q41733983 | Relationship between inflammatory cytokines and cardiorenal anemia syndrome: treatment with recombinant human erythropoietin (rhepo). |
| Q47111895 | Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease |
| Q37200548 | Renal disease: a common and a silent killer |
| Q35151878 | Resistance to erythropoiesis stimulating agents in patients treated with online hemodiafiltration and ultrapure low-flux hemodialysis: results from a randomized controlled trial (CONTRAST) |
| Q53096541 | Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter? |
| Q36937327 | Restoring invisible and abandoned trials: a call for people to publish the findings |
| Q37534821 | Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease |
| Q41860936 | Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients |
| Q35577092 | Role of vascular function in predicting arteriovenous fistula outcomes: an observational pilot study |
| Q64111741 | Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial |
| Q26745888 | SPRINT: The Study Nephrologists Might Take With a Grain of Salt |
| Q33985838 | Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes |
| Q73290174 | Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists |
| Q35141918 | Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity |
| Q49680628 | Should We Increase GFR with Bardoxolone in Alport Syndrome? |
| Q42931999 | Should glucose-sparing prescriptions be expected to reduce the cardiovascular risk of peritoneal dialysis patients? |
| Q31073395 | Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study. |
| Q38051056 | Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations? |
| Q37670331 | Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose |
| Q41123077 | Similar Outcomes for Two Anemia Treatment Strategies among Elderly Hemodialysis Patients with Diabetes |
| Q33532601 | Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease |
| Q92346724 | Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification |
| Q34493460 | Stable hemoglobin in hemodialysis patients: forest for the trees--a 12-week pilot observational study |
| Q38556990 | State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists |
| Q42593974 | Stimulating erythropoiesis in inflammatory bowel disease associated anemia |
| Q27694667 | Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis |
| Q41621194 | Successful creation of an anemia management algorithm for hemodialysis patients |
| Q35917499 | Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients |
| Q94526892 | Target haemoglobin concentrations in chronic kidney disease |
| Q57772073 | Target haemoglobin concentrations in chronic kidney disease |
| Q44649509 | Target hemoglobin trials in chronic kidney disease: design and interpretation issues |
| Q38042223 | Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis |
| Q36315311 | Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study |
| Q38091580 | Targets, trends, excesses, and deficiencies: refocusing clinical investigation to improve patient outcomes |
| Q90428600 | Testing two (of several) intravenous iron dosing strategies in hemodialysis |
| Q36687012 | The American Society of Nephrology at 50: A Personal Perspective |
| Q36073903 | The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease |
| Q35849765 | The Different Association between Serum Ferritin and Mortality in Hemodialysis and Peritoneal Dialysis Patients Using Japanese Nationwide Dialysis Registry |
| Q57174517 | The Incidence and Pathophysiology of the Obesity Paradox: Should Peritoneal Dialysis and Kidney Transplant Be Offered to Patients with Obesity and End-Stage Renal Disease? |
| Q92921916 | The Influence of Inflammation on Anemia in CKD Patients |
| Q49168187 | The Kidney Disease: improving Global Outcomes website: comparison of guidelines as a tool for harmonization |
| Q35801832 | The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients |
| Q38496987 | The Labile Side of Iron Supplementation in CKD |
| Q46035828 | The MAINTAIN study--managing hemoglobin variability with darbepoetin alfa in dialysis patients experiencing a severe drop in hemoglobin. |
| Q46726047 | The Medicare Access and CHIP Reauthorization Act: Implications for Nephrology |
| Q38821770 | The Obesity Paradox in Kidney Disease: How to Reconcile it with Obesity Management |
| Q38740871 | The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease |
| Q61798493 | The association of the difference in hemoglobin levels before and after hemodialysis with the risk of 1-year mortality in patients undergoing hemodialysis. Results from a nationwide cohort study of the Japanese Renal Data Registry |
| Q58795386 | The authors' reply |
| Q36896011 | The case for intervention bias in the practice of medicine |
| Q37231779 | The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions |
| Q36631500 | The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients. |
| Q98177250 | The current and future landscape of dialysis |
| Q35017465 | The effect of altitude change on anemia treatment response in hemodialysis patients |
| Q36736806 | The effect of altitude on dosing and response to erythropoietin in ESRD |
| Q79837170 | The effect of epoetin dose on hematocrit |
| Q35692440 | The effect of high-flux hemodialysis on hemoglobin concentrations in patients with CKD: results of the MINOXIS study |
| Q33234889 | The effects of nocturnal hemodialysis compared to conventional hemodialysis on change in left ventricular mass: rationale and study design of a randomized controlled pilot study |
| Q33939447 | The elderly patients on hemodialysis |
| Q36547323 | The epidemics of cardiovascular disease in elderly patients with chronic kidney disease--two facets of the same problem |
| Q38798407 | The future of intravenous iron in nephrology |
| Q37068266 | The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measure |
| Q36072666 | The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial |
| Q83307973 | The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients |
| Q43608007 | The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study |
| Q28194293 | The importance of anemia and its correction in the management of severe congestive heart failure |
| Q33412890 | The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data |
| Q34193545 | The influence of Erythropoietin on platelet activation, thrombin generation and FVII/active FVII in patients with AMI. |
| Q51121094 | The influence of age on changes in health-related quality of life over three years in a cohort undergoing hemodialysis. |
| Q37542851 | The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients |
| Q30446840 | The mortality risk associated with higher hemoglobin: is the therapy to blame? |
| Q35758558 | The new FDA labeling for ESA--implications for patients and providers |
| Q48422674 | The normal HCT trial re-revisited: what were the actual findings? |
| Q33646679 | The role of anemia management in improving outcomes for African-Americans with chronic kidney disease |
| Q43054143 | The role of platelets in atherosclerosis, diabetes mellitus, and chronic kidney disease. An attempt at explaining the TREAT study results |
| Q44363438 | The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations |
| Q36947417 | Therapeutic potential of erythropoietin in cardiovascular disease: erythropoiesis and beyond |
| Q39291945 | Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies. |
| Q95810354 | Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome |
| Q36581425 | Therapy insight: management of cardiovascular disease in the renal transplant recipient |
| Q33348067 | Thrombosis in End‐Stage Renal Disease |
| Q83317996 | Time to consider the role of epoetin |
| Q35047211 | Transfusion medicine: looking to the future |
| Q41836951 | Transplantation of genetically engineered cardiac fibroblasts producing recombinant human erythropoietin to repair the infarcted myocardium. |
| Q36285948 | Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations |
| Q90709671 | Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) |
| Q40540575 | Treatment of anemia in chronic kidney disease: known, unknown, and both |
| Q34064046 | Treatment of anemia in heart failure: potential risks and benefits of intravenous iron therapy in cardiovascular disease |
| Q80349184 | Treatment of anemia in the patient with heart failure |
| Q41387413 | Treatment of renal anemia: Erythropoiesis stimulating agents and beyond |
| Q34857944 | Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). |
| Q35056402 | Trends in anemia management in US hemodialysis patients 2004-2010 |
| Q88498966 | Trends in the treatment of chronic kidney disease-associated anaemia in a cohort of haemodialysis patients: the Irish experience |
| Q64110375 | Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis |
| Q61866159 | Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS) |
| Q50547672 | Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia. |
| Q41229491 | Use of Aspirin in normalization of recombinant human erythropoietin-mediated hyper-reactivity of platelets in rats. |
| Q37368733 | Use of agents stimulating erythropoiesis in digestive diseases |
| Q92373776 | Usefulness of mid-week hemoglobin measurement for anemia management in patients undergoing hemodialysis: a retrospective cohort study |
| Q35851384 | Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients |
| Q82774685 | Vitamin D deficiency and anemia in early chronic kidney disease |
| Q35782007 | Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward |
| Q48196600 | What crit? |
| Q37778263 | What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? |
| Q73819961 | When should we start erythropoietin therapy? |
| Q36666760 | White thrombus formation in blood tubing lines in a chronic hemodialysis unit |
| Q49064969 | Why does the treatment of anaemia not improve cardiac outcomes in CKD? |
| Q33882103 | Why is protein-energy wasting associated with mortality in chronic kidney disease? |
| Q82564790 | [Correction of anemia in renal insufficiency: what target?] |
| Q84569484 | [Hemoglobin rate and cardiovascular risk] |
| Q54434317 | [Iron deficiency, thrombocytosis and thromboembolism]. |
| Q87061028 | [Patient Blood Management : three pillar strategy to improve outcome through avoidance of allogeneic blood products] |
| Q82520568 | [Renal anemia - an important secondary disease in renal insufficiency] |
| Q79314860 | [Therapy and prophylaxis of renal failure] |
| Q84385085 | [Update on the management of anemia. Nephrology World Congress 2009] |
Search more.